|
Shares Outstanding: 59,366,332
|
Exchange in U.S. OTC BB: BIOHF
|
|
Active Float:
20,000,000 (approx.)
|
Recent Market Capitalization: $12,000,000 (US)
|
|
Exchange in Canada: CDNX: BIO.V
|
U.S. S.E.C. Registration Number: 0 – 29108
|
|
52-Week High / Low
OTC:BB: 0.41 / 0.07
|
52-Week High / Low
CDNX: 0.65 / 0.12
|
|
|
The
Company: Biotech is a pharmaceutical company based in Vancouver,
Canada that has developed and is now marketing a breakthrough drug for the
treatment of Type ll diabetes. Type ll Diabetes affects more than 18 million
Americans and more than150 million people world wide. Biotech has patent
protection in the U.S until 2020 for its DIAB II drug.
The Drug:
DIAB II is broadly classed as an insulin-sensitizing drug.
Drugs of this type improve the body’s ability to make use of insulin.
Insulin-sensitizing drugs such as Avandia and Actos which fall in the
glitazone class have a number of drawbacks including potential liver
toxicity. DIAB II does not have these drawbacks and is a remarkably
safe drug. Clinical studies have shown dramatic results. DIAB II can be
taken by itself or together with other Type II Diabetes Treatments as a
combination therapy.
The
Potential Market: The Type II Diabetes drug market worldwide
has an estimated value of over $10 Billion. Biotech has begun the
process of obtaining regulatory approvals for its drug in markets around the
world.
The
Future: Biotech Holdings and DIAB II are beginning to receive
recognition for their breakthrough drug and for the revenue implications of
the patent. Research this stock while the company that developed, controls
and markets it is still a penny stock.
|
|
Biotech
Holdings is moving ahead with achieving regulatory approvals for its
revolutionary new diabetes drug, DIAB II.
On November 5, 2001 Biotech
announced its first Western Hemisphere approval for DIAB II --- pharmaceutical regulators in Peru,
after considering a complete file on DIAB II, granted the drug full approval
for sale in Peru. Now the attention for the next approval will swing to
Mexico, where Biotech made a detailed application to pharmaceutical
regulators on September 18th, 2001. Mexico is one of the fastest-growing
global pharmaceutical markets and by 2005 will be the seventh-largest
pharmaceutical market in the world.
With the approval from Peru in hand, Biotech is planning for the outcome
of an expedited approval process in Mexico. An approval in Mexico will mean that the market potential for DIAB II
has achieved a critical mass, triggering the immediate application of funds
for DIAB II tableting and packaging, so that the flow of this important
diabetes drug to the Latin American market can begin.
In the
meantime, in the U.S. and Europe, Biotech
is in discussions with major pharmaceutical companies who are interested in
the potential of DIAB II both as a mono-therapy and as a combination
therapy for major markets including the United States.
In
addition to the growing potential of DIAB II, the President of Biotech has now been granted two U.S. patents - on
November 28, 2000 and September 18, 2001 - for the sole right to the use
of any insulin-sensitizing drug together with other Type II Diabetes
treatments such as sulfonylurea (pancreas-stimulating) drugs,
alpha-glucosidase drugs or insulin itself.
The President has already assigned all uses of DIAB II in combination
to Biotech Holdings. This provides the opportunity for the Company to joint
venture, with major drug companies, many new drugs for the treatment of all
forms of diabetes.
|
![[<--]](/icons/prev.gif){kind=icon}
![[-->]](/icons/next.gif){kind=icon}